Pain and Perception: Exploring Psychedelics as Novel Therapeutic Agents in Chronic Pain Management.

IF 3.2 2区医学 Q2 CLINICAL NEUROLOGY

Current Pain and Headache Reports Pub Date : 2025-01-07 DOI:10.1007/s11916-024-01353-0

Natalie H Strand, Madeline Whitney, Brooks Johnson, Tyler Dunn, Sumedha Attanti, Jillian Maloney, Lopa Misra, Diego Gomez, Omar Viswanath, Eric Emami, James Leathem

{"title":"Pain and Perception: Exploring Psychedelics as Novel Therapeutic Agents in Chronic Pain Management.","authors":"Natalie H Strand, Madeline Whitney, Brooks Johnson, Tyler Dunn, Sumedha Attanti, Jillian Maloney, Lopa Misra, Diego Gomez, Omar Viswanath, Eric Emami, James Leathem","doi":"10.1007/s11916-024-01353-0","DOIUrl":null,"url":null,"abstract":"Purpose of review: Chronic pain affects approximately 1.5 billion people worldwide, representing the leading cause of disability and a significant financial burden on healthcare systems. Conventional treatments, such as opioids and non-steroidal anti-inflammatory drugs, are frequently linked to adverse effects, including dependency and gastrointestinal issues, and often offer limited long-term relief. This review explores the potential of psychedelics, including psilocybin, LSD, and ketamine, as alternative therapeutic agents in chronic pain management.Recent findings: These substances modulate pain perception through actions on serotonergic and glutamatergic systems and may promote neuroplasticity, offering novel pathways for pain relief. Specifically, the review details the pharmacologic actions of psychedelics, their effects on chronic pain syndromes such as cancer pain, migraines, and neuropathic pain, and their clinical implications. The safety profiles, patient responses, and analgesic properties of these compounds are examined, highlighting the need for further research to validate their efficacy and optimize their therapeutic use in pain management.","PeriodicalId":50602,"journal":{"name":"Current Pain and Headache Reports","volume":"29 1","pages":"15"},"PeriodicalIF":3.2000,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Pain and Headache Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11916-024-01353-0","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Chronic pain affects approximately 1.5 billion people worldwide, representing the leading cause of disability and a significant financial burden on healthcare systems. Conventional treatments, such as opioids and non-steroidal anti-inflammatory drugs, are frequently linked to adverse effects, including dependency and gastrointestinal issues, and often offer limited long-term relief. This review explores the potential of psychedelics, including psilocybin, LSD, and ketamine, as alternative therapeutic agents in chronic pain management.

Recent findings: These substances modulate pain perception through actions on serotonergic and glutamatergic systems and may promote neuroplasticity, offering novel pathways for pain relief. Specifically, the review details the pharmacologic actions of psychedelics, their effects on chronic pain syndromes such as cancer pain, migraines, and neuropathic pain, and their clinical implications. The safety profiles, patient responses, and analgesic properties of these compounds are examined, highlighting the need for further research to validate their efficacy and optimize their therapeutic use in pain management.

查看原文本刊更多论文

疼痛和知觉：探索致幻剂作为慢性疼痛管理的新型治疗剂。

综述目的：慢性疼痛影响全球约15亿人，是导致残疾的主要原因，也是卫生保健系统的重大经济负担。阿片类药物和非甾体类抗炎药等常规治疗方法往往与不良反应有关，包括依赖性和胃肠道问题，而且往往只能提供有限的长期缓解。这篇综述探讨了迷幻药的潜力，包括裸盖菇素、LSD和氯胺酮，作为慢性疼痛管理的替代治疗药物。最近的研究发现：这些物质通过对血清素和谷氨酸能系统的作用来调节疼痛感知，并可能促进神经可塑性，为缓解疼痛提供了新的途径。具体来说，这篇综述详细介绍了致幻剂的药理作用，它们对慢性疼痛综合征（如癌症疼痛、偏头痛和神经性疼痛）的影响，以及它们的临床意义。对这些化合物的安全性、患者反应和镇痛特性进行了研究，强调需要进一步研究以验证其疗效并优化其在疼痛管理中的治疗用途。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Pain and Headache Reports CLINICAL NEUROLOGY-

CiteScore

6.10

自引率

2.70%

发文量

审稿时长

6-12 weeks

期刊介绍： This journal aims to review the most important, recently published clinical findings regarding the diagnosis, treatment, and management of pain and headache. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care and prevention of pain and headache. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as anesthetic techniques in pain management, cluster headache, neuropathic pain, and migraine. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.